Business Wire

NY-JEFFERIES-FINANCIAL

28.5.2020 18:04:07 CEST | Business Wire | Press release

Share
Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent

Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease.

Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000.

“We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charities globally as this is truly a tragedy that affects all of us and, in particular, those who are most disadvantaged and in the greatest need.

The charities selected are both big and small and represent everything from food banks, child care services, assistance with PPE and other medical supplies, support for front line medical workers, assistance for afflicted military personnel, local teen centers, support for police and fire, workforce training and re-training and many other worthy areas that are most in need. We thank our employees and clients for aiding in the selection of many of these remarkable charities.

Finally, all of us at Jefferies would like to thank all the dedicated professionals working tirelessly on the front line to help those in need. They are the true heroes whom we are honored to help in Peg’s name.”

Contributions in the following amounts will be immediately distributed to these respected organizations:

NYC Mayor’s Fund | Peg’s Cure

 

$ 150,000

All Hands and Hearts

 

$ 150,000

American Heart Association

$ 150,000

Bowery Mission

$ 150,000

Hackensack Meridian Health Foundation

$ 150,000

Houston Police Foundation

 

$ 150,000

International Rescue Committee

 

$ 150,000

Robin Hood Foundation

 

$ 150,000

Strive

 

$ 150,000

The Bass Foundation

 

$ 150,000

World Central Kitchen

 

$ 150,000

We Can #TogetherFromHome

 

$ 100,000

Achievement First

 

$ 100,000

Aktion Deutschland Hilft

 

$ 100,000

Alzheimer’s Association

 

$ 100,000

Ambitious About Autism

 

$ 100,000

Barnardo’s

$ 100,000

BMS Family Health and Wellness Center

 

$ 100,000

Bob Woodruff Foundation

 

$ 100,000

Boys & Girls Clubs of the Austin Area

 

$ 100,000

Brewers Community Foundation

 

$ 100,000

Buttle UK

 

$ 100,000

Central Texas Food Bank

 

$ 100,000

Chelsea and Westminster Hospital NHS Foundation Trust

 

$ 100,000

Chrysalis

$ 100,000

City Harvest

$ 100,000

Citymeals on Wheels

 

$ 100,000

Columbia Children's Hospital

 

$ 100,000

Community Food Bank of New Jersey

 

$ 100,000

Covenant House

 

$ 100,000

Doctors Without Borders

 

$ 100,000

East High – EOP (Education Partnership Organization)

 

$ 100,000

Elmhurst Hospital Charity

 

$ 100,000

Family Promise of Bergen County

 

$ 100,000

FarmLink

 

$ 100,000

Feeding America

 

$ 100,000

Food Bank For New York City

 

$ 100,000

Foodlink

 

$ 100,000

Habitat for Humanity Japan

 

$ 100,000

Hance Family Foundation

 

$ 100,000

Humanity & Inclusion

 

$ 100,000

Hunger Free America

 

$ 100,000

Imperial Health Charity

 

$ 100,000

Kids in Crisis

 

$ 100,000

Kohka Foundation

 

$ 100,000

Lahey Clinic Foundation

 

$ 100,000

Mail Force Charity

 

$ 100,000

Martha’s Table

 

$ 100,000

Médecins Sans Frontières

 

$ 100,000

Memorial Hermann Foundation

 

$ 100,000

My Sister's Place

 

$ 100,000

National Emergencies Trust

 

$ 100,000

Navajo Nation Covid-19 Relief Fund

 

$ 100,000

Nazareth Housing

 

$ 100,000

Neighbourly Community Fund

 

$ 100,000

NHS Charities Together

 

$ 100,000

Northwell Health's COVID-19 Emergency Fund

 

$ 100,000

NYU Langone

 

$ 100,000

Off Their Plate

 

$ 100,000

Oxfam India

 

$ 100,000

Philippine Disaster Resilience Foundation

 

$ 100,000

Red Hook Initiative

 

$ 100,000

Rosetree Trust

 

$ 100,000

Royal College of Nursing Foundation

 

$ 100,000

RVNAhealth

 

$ 100,000

Second Harvest

 

$ 100,000

Sempre Con Voi (Always with You)

 

$ 100,000

St Michael’s House

 

$ 100,000

TBD 1

 

$ 100,000

TBD 2

 

$ 100,000

TBD 3

 

$ 100,000

TCF Bank

 

$ 100,000

The Care Workers Charity

 

$ 100,000

The River Fund New York

 

$ 100,000

The United Way of Central Indiana COVID-19 Relief Fund

 

$ 100,000

The World Health Organization (WHO)

 

$ 100,000

Trinity's Services & Food for the Homeless

 

$ 100,000

The Trussell Trust

 

$ 100,000

UNICEF

 

$ 100,000

UR Medicine Home Care’s Meals on Wheels

 

$ 100,000

URMC COVID-19 Emergency Fund

 

$ 100,000

Valpo Surf Project, Inc.

 

$ 100,000

Volunteers of Legal Service

 

$ 100,000

Our Dream Their Smile

 

$ 100,000

West Side Campaign Against Hunger

 

$ 100,000

Women United in Philanthropy

 

$ 100,000

Women's Center of Greater Danbury

 

$ 100,000

 

 


$ 9,250,000

Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye